
CorMedix (CRMD) Stock Forecast & Price Target
CorMedix (CRMD) Analyst Ratings
Bulls say
Cormedix Inc. has demonstrated a strong financial performance by raising its full-year 2025 pro forma net revenue guidance to $390–$410 million, surpassing its previous estimate of at least $375 million, driven by increased adoption of DefenCath and contributions from the Melinta portfolio. The company also anticipates fourth-quarter net revenue between $115 million and $135 million, indicating robust momentum heading into the year-end. Additionally, the projected fully synergized pro forma adjusted EBITDA range of $220–$240 million further reinforces the positive outlook for Cormedix's financial health and growth trajectory.
Bears say
Cormedix is facing significant uncertainty due to the TDAPA pricing headwind, which could negatively impact its revenue potential and gross margin from its product, DefenCath. While there is a recognition of a potential $100 million to $200 million market opportunity with Niyadas, the reliance on strategic commercial infrastructure in a single market, the United States, poses a risk to sustained profitability. Overall, despite some anticipated tailwinds, the financial outlook remains encumbered by pricing uncertainties that could adversely affect EBITDA margins in the near term.
This aggregate rating is based on analysts' research of CorMedix and is not a guaranteed prediction by Public.com or investment advice.
CorMedix (CRMD) Analyst Forecast & Price Prediction
Start investing in CorMedix (CRMD)
Order type
Buy in
Order amount
Est. shares
0 shares